Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular ...

Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to ...

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade ...

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade ...

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

Discover how saliva testing detects oral and systemic diseases early. Learn about the mouth-body connection and the power of salivary biomarkers. [ ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlu ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Arteries can narrow with fatty buildup. Blood struggles to move. Oxygen drops. A heart attack can follow, and it remains the world’s top killer. Researchers at the University of California San Diego ...